Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Provectus Pharmatech, Inc.”

25 pharma patents match "Provectus Pharmatech, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 25
Index total 30,257
Page 1 / 2

Quick answer

This filtered view shows 25 pharmaceutical patents matching "Provectus Pharmatech, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

25 results for “Provectus Pharmatech, Inc.” · 30,257 patents in full index Clear search

  1. US 12377068

    In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors

    Provectus Pharmatech, Inc. · Granted Aug 5, 2025 · Expires Jul 31, 2045

    granted
  2. US 12133840

    Halogenated xanthene composition and method for treating hematologic cancers

    Provectus Pharmatech, Inc. · Granted Nov 5, 2024 · Expires Oct 31, 2044

    granted
  3. US 12064507

    Composition and method for oral treatment of leukemia

    Provectus Pharmatech, Inc. · Granted Aug 20, 2024 · Expires Aug 15, 2044

    granted
  4. US 11975106

    Uses of halogenated xanthenes in oncology and virology

    Provectus Pharmatech, Inc. · Granted May 7, 2024 · Expires May 2, 2044

    granted
  5. US 11974980

    In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors

    Provectus Pharmatech, Inc. · Granted May 7, 2024 · Expires May 2, 2044

    granted
  6. US 11938182

    Halogenated xanthenes as vaccine adjuvants

    Provectus Pharmatech, Inc. · Granted Mar 26, 2024 · Expires Mar 21, 2044

    granted
  7. US 11426379

    Combination of local and systemic therapies for enhanced treatment of dermatologic conditions

    Provectus Pharmatech, Inc. · Granted Aug 30, 2022 · Expires Aug 25, 2042

    granted
  8. US 11419844

    Halogenated xanthene composition and method for treating hematologic cancers

    Provectus Pharmatech, Inc. · Granted Aug 23, 2022 · Expires Aug 18, 2042

    granted
  9. US 11071781

    Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer

    Provectus Pharmatech, Inc. · Granted Jul 27, 2021 · Expires Jul 22, 2041

    granted
  10. US 11058664

    In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors

    Provectus Pharmatech, Inc. · Granted Jul 13, 2021 · Expires Jul 8, 2041

    granted
  11. US 10471144

    Combination of local rose bengal and systemic immunomodulative therapies for enhanced treatment of cancer

    Provectus Pharmatech, Inc. · Granted Nov 12, 2019 · Expires Nov 7, 2039

    granted
  12. US 10130658

    Method of ex vivo enhancement of immune cell activity for cancer immunotherapy with a small molecule ablative compound

    Provectus Pharmatech, Inc. · Granted Nov 20, 2018 · Expires Nov 15, 2038

    granted
  13. US 9839688

    Combination of rose bengal and systemic immunomodulative therapies for enhanced treatment of cancer

    Provectus Pharmatech, Inc. · Granted Dec 12, 2017 · Expires Dec 7, 2037

    granted
  14. US 9808524

    Combination of local and systemic immunomodulative therapies for melanoma and liver cancer

    Provectus Pharmatech, Inc. · Granted Nov 7, 2017 · Expires Nov 2, 2037

    granted
  15. US 9422260

    Process for the synthesis of 4,5,6,7-tetrachloro-3′,6′-dihydroxy-2′,4′,5′,7′-tetraiodo-3H-spiro[isobenzofuran-1,9′-xanthen]-3-one(Rose Bengal) and related xanthenes

    Provectus Pharmatech, Inc. · Granted Aug 23, 2016 · Expires Aug 18, 2036

    granted
  16. US 8974363

    Topical medicaments and methods for photodynamic treatment of disease

    Provectus Pharmatech, Inc. · Granted Mar 10, 2015 · Expires Mar 5, 2035

    granted
  17. US 8557298

    Medicaments for chemotherapeutic treatment of disease

    Provectus Pharmatech, Inc. · Granted Oct 15, 2013 · Expires Oct 10, 2033

    granted
  18. US 8470296

    Intracorporeal medicaments for high energy phototherapeutic treatment of disease

    Provectus Pharmatech, Inc. · Granted Jun 25, 2013 · Expires Jun 20, 2033

    granted
  19. US 7863047

    Intracorporeal medicaments for photodynamic treatment of disease

    Provectus Pharmatech, Inc. · Granted Jan 4, 2011 · Expires Dec 30, 2030

    granted
  20. US 7648695

    Medicaments for chemotherapeutic treatment of disease

    Provectus Pharmatech, Inc. · Granted Jan 19, 2010 · Expires Jan 14, 2030

    granted
  21. US 7427389

    Diagnostic agents for positron emission imaging using radiolabeled halogenated xanthenes

    Provectus Pharmatech, Inc. · Granted Sep 23, 2008 · Expires Sep 18, 2028

    granted
  22. US 7402299

    Intracorporeal medicaments for photodynamic treatment of disease

    Provectus Pharmatech, Inc. · Granted Jul 22, 2008 · Expires Jul 17, 2028

    granted
  23. US 7390668

    Intracorporeal medicaments for photodynamic treatment of disease

    Provectus Pharmatech, Inc. · Granted Jun 24, 2008 · Expires Jun 19, 2028

    granted
  24. US 7384623

    High energy phototherapeutic agents

    Provectus Pharmatech, Inc. · Granted Jun 10, 2008 · Expires Jun 5, 2028

    granted